Elsevier Inc.

SHERPA: Unknown

People

  1. Paik
    Paik
  2. Drilon
    Drilon
  3. Wu
    Wu
  4. Chaft
    Chaft
  5. Kris
    Kris
  6. Rekhtman
    Rekhtman
  7. Riely
    Riely
  8. Gelblum
    Gelblum
  9. Zhang
    Zhang
  10. Berger
    Berger

Groups

  1. Department of Medicine (57)
  2. Solid Tumor Oncology Division (57)
  3. Thoracic Oncology (57)
  4. GSK Faculty (10)
  5. Radiation Oncology, Department of (10)
  6. Sloan Kettering Institute Postdocs (8)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  8. Human Oncology and Pathogenesis Program (6)
  9. Biostatistics Service (5)
  10. Epidemiology and Biostatistics (5)
Search Within
  1. "Meeting abstract"
  2. "Paul Paik"
  3. "Solid Tumor Oncology Division"
Formats
  1. Meeting Abstract (57)
Groups
  1. Department of Medicine (57)
  2. Solid Tumor Oncology Division (57)
  3. Thoracic Oncology (57)
  4. GSK Faculty (10)
  5. Radiation Oncology, Department of (10)
  6. Sloan Kettering Institute Postdocs (8)

More Groups

People
  1. Paul Paik (57)
  2. Abraham Wu (10)
  3. Alexander Drilon (10)
  4. Andreas Rimner (10)
  5. Jamie Chaft (9)
  6. Mark Kris (8)

More People

Years
  1. 2023 (9)
  2. 2022 (7)
  3. 2021 (12)
  4. 2019 (1)
  5. 2018 (7)
  6. 2017 (2)

More Years

Publications
  1. Journal of Thoracic Oncology (46)
  2. International Journal of Radiation Oncology, Biology, Physics (9)
  3. European Journal of Cancer (2)

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tepotinib and capmatinib in patients with MET exon 14 skipping NSCLC: A matching adjusted indirect comparison (MAIC)
    Meeting Abstract

    Pfeiffer, B. M.; Postma, M. J.; Hatswell, A.; Vioix, H.; Paik, P. K.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Tepotinib in Asian patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in long-term follow-up from VISION
    Meeting Abstract

    Ahn, M. J.; Kato, T.; Yang, J. C. H.; Sakai, H.; Morise, M.; Chen, Y. M.; Han, J. Y.; Yang, J. J.; Zhao, J.; Hsia, T. C.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Initial chemotherapy for locally advanced and metastatic NUT carcinoma
    Meeting Abstract

    Luo, J.; Finstein, B.; Sanchez, M.; Lee, E.; Hertzler, H.; Luong, N.; Tamen, R.; Brisbane, G.; Nguyen, T.; Paik, P. K.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • ctDNA dynamics, prognostic markers and resistance mechanisms in tepotinib-treated METex14 skipping NSCLC in the VISION trial
    Meeting Abstract

    Le, X.; Garassino, M. C.; Ahn, M. J.; Felip, E.; Cortot, A. B.; Sakai, H.; Mazieres, J.; Thomas, M.; Viteri, S.; Conte, P.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Analysis of all patients from VISION Cohorts A and C
    Meeting Abstract

    Garassino. M. C.; Thomas, M.; Felip. E.; Sakai. H.; Le, X.; Veillon, R.; Smith. E. F.; Mazieres, J.; Cortot, A. B.; Raskin, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Treatment sequencing in the VISION study of tepotinib in patients with METexon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Griesinger, F.; Garassino, M. C.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F.; Raskin, J.; Thomas, M.; Ahn, M. J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • A randomized, open-label phase 2 study of the TORC 1/2 inhibitor sapanisertib in relapsed/refractory (R/R) NFE2l2 (NRF2)-mutated and wild-type (WT) squamous non-small cell lung cancer (sqNSCLC)
    Meeting Abstract

    Riess, J. W.; Johnson, M. L.; Gadgeel, S.; Skoulidis, F.; Sumrow, B.; Kuriakose, E.; Albert, K.; Kittrell, N.; Akella, L.; Fiji, G.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical response to tepotinib according to circulating tumor (ct)DNA biomarkers in patients with advanced/metastatic NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx)
    Meeting Abstract

    Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Cabrera-Galvez, C.; Baz, D. V.; Kim, Y. C.; Kang, J. H.; Stroh, C.; Juraeva, D.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Primary analysis of the confirmatory VISION cohort C
    Meeting Abstract

    Thomas, M.; Garassino, M.; Felip, E.; Sakai, H.; Le, X.; Veillon, R.; Smit, E.; Mazieres, J.; Cortot, A.; Raskin, J.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save